Impact of Diabetes Status on Immunogenicity of Trivalent Inactivated Influenza Vaccine in Older Adults

Sarah Spencer¹, Jessie R. Chung¹, Edward A. Belongia², Maria Sundaram², Jennifer Meece², Laura A. Coleman², Richard Zimmerman³, Mary Patricia Nowalk³, Krissy K. Moehling³, Ted Ross³, Chalise E. Carter³, David Shay¹, Min Levine¹, Justine Liepkalns¹, Jin Hyang Kim¹, Suryaprakash Sambhara¹, Mark Thompson¹, Brendan Flannery¹

¹US Centers for Disease Control and Prevention, Influenza Division, Atlanta, GA

²Marshfield Clinic Research Institute, Marshfield, WI

³University of Pittsburgh Schools of Health Sciences, Pittsburgh, PA

Current affiliations:

Ted Ross, Chalise Carter: Center for Vaccines and Immunology, Department of Infectious Diseases, University of Georgia, Athens, Georgia, USA tedross@uga.edu

Justine Liepkalns: University of Washington, Seattle, WA jsliepk@uw.edu

Jin Hyang Kim: Arbutus Biopharma, Warminster, PA jkim@arbutusbio.com

Laura Coleman: Novartis Institutes for Biomedical Research laura.coleman@novartis.com

Word count: Abstract 72, Text 1919

Abstract

Individuals with type 2 diabetes mellitus experience high rates of influenza virus infection and complications. We compared the magnitude and duration of serologic response to trivalent influenza vaccine in adults aged 50-80 with and without type 2 diabetes mellitus. Serologic response to influenza vaccination was similar in both groups: greater fold-increases in antibody titer occurred among individuals with lower pre-vaccination antibody titers. Waning of antibody titers was not influenced by diabetes status.

Key words: influenza, vaccine, serologic response

Background

Individuals with type 2 diabetes mellitus are at increased risk of influenza complications following influenza virus infection¹. Influenza vaccination has been recommended for persons of all ages with diabetes since 1960². It is unknown if poor immunological response to vaccination contributes to the high risk of influenza-related complications among diabetic adults¹. Prior studies have suggested no impairment of serologic response to influenza vaccination among diabetic compared to non-diabetic adults^{3,4}. However, other factors, such as age, obesity, control of diabetes, serum vitamin D concentrations and medications may be associated with vaccine response among diabetics³⁻⁸. For example, increasing age has been associated with decreased vaccine response⁵ and obesity has been shown to be associated with increased decay of antibody titers over time⁸. Another hypothesis suggests that immunomodulatory medications that are routinely recommended for persons with diabetes, such as statins, lead to decreased immune response to vaccination due to their anti-inflammatory effect⁹. One study of hospitalized adults with influenza A(H1N1)pdm09 virus-associated illness found that diabetes was not associated with severity of influenza virus infection after controlling for obesity¹⁰. The duration of immune response to influenza vaccination and the decline of antibody titers over time has been explored in studies of serologic response to vaccination and vaccine effectiveness^{11,12}, but has not been thoroughly investigated among diabetics. The objective of the present study was to assess whether presence of type 2 diabetes affected the magnitude and duration of antibody response to influenza vaccination among older adults.

Methods

Participants were recruited from study sites in outpatient medical facilities in Marshfield, Wisconsin and Pittsburgh, Pennsylvania, as described previously¹³. Approximately equal numbers of adults with type 2 diabetes and non-diabetic adults were targeted for recruitment at each site. Diabetes status was determined by medical record documentation. Eligible participants aged 50–80 years who had not received the 2011–2012 influenza vaccine were enrolled from August–November, 2011. The enrollment period preceded influenza circulation in these communities. Exclusion criteria included documented contraindications to receipt of inactivated influenza vaccine¹⁴, Guillain-Barré syndrome, dementia or Alzheimer disease, estimated life expectancy <2 years, immunosuppressive medical treatment or immunocompromising condition, or concurrent participation in another

influenza vaccine research study. Consented participants had blood drawn prior to receiving the 2011–2012 standard-dose trivalent inactivated influenza vaccine (IIV3) and 17-28 days post-vaccination. Participants that returned for the second year of the study received a third blood draw in the fall of 2012 prior to the circulation of influenza. Serum samples were aliquoted and frozen at –80°C until assayed. Study procedures, informed consent and data collection documents were reviewed and approved by Institutional Review Boards of Marshfield Clinic, the University of Pittsburgh, and the Centers for Disease Control and Prevention.

Laboratory Procedures

Serology reference viruses for the 2011–2012 influenza season included A/California/07/2009 (H1N1pdm09), A/Victoria/210/2009(H3N2) (A/Perth/16/09-like), and B/Brisbane/60/2008 (Victoria lineage). In addition, sera from patients enrolled in the 2012-2013 influenza season were tested against A/California/07/2009 (H1N1pdm09), A/Victoria/361/2011(H3N2), B/Brisbane/60/2008 (Victoria lineage), and B/Wisconsin/01/2010 (Yamagata lineage) viruses. Hemagglutination inhibition (HI) assays were performed with pre- and post-vaccination serum specimens as previously described¹⁵ using 0.5% turkey erythrocytes. HI assays were conducted simultaneously on paired pre- and post-vaccine sera or paired post-vaccine and day 365 sera from each participant at the Battelle Memorial Laboratory (Aberdeen, Maryland). Sera were diluted 2-fold starting from 1:10 and tested in duplicate. The HI titer was the reciprocal of the serum dilution in the last well with complete hemagglutination inhibition. The final HI titer was estimated as the geometric mean of duplicate samples; a value of 5 was used for HI <10.

Induction of vaccine antigen-specific memory B-cells (IgG, IgM and IgA) was evaluated by an ELISPOT assay, using a paired set of day 0 and day 21 peripheral blood mononuclear cells (PBMCs) stimulated *in vitro* for 5 days with polyclonal stimuli as previously described¹⁶. For serum vitamin D levels, 25-hydroxyvitamin D concentrations (ng/mL) were measured with a Waters ultra-performance liquid chromatography with tandem mass spectrometer, as previously described⁶.

Statistical Analysis

We compared descriptive characteristics of diabetic and non-diabetic participants using the χ^2 test for categorical variables and Student's *t*-test for continuous variables. Geometric mean titers (GMT), GMT ratios, and 95% confidence intervals (CI) were calculated using repeated measures linear mixed models as previously described¹⁶. Seroconversion was defined as a four-fold rise or greater in HI titer with a final titer ≥ 40 . Seroprotection was defined as titer ≥ 40 on the second serum sample. Rate of change between Day 21 and Day 365 was defined as the difference in log₂-transformed titer. Time in days to decrease one 2-fold dilution in HI titer was calculated as the reciprocal of the model estimated rates, assuming linear (log₂) decay over time, as described¹¹. We used linear regression with log₂-transformed fold-rise as the dependent variable to identify associations between antibody waning and factors including pre-vaccination HI titer, post-vaccination titer, age (in years), diabetes status, serum vitamin D concentration (<30 or ≥ 30 ng/mL)⁶, and impaired functional status (positive response to any of five functional status-related questions [Supplemental Table 2]). Those who seroconverted between Day 21 and Day 365 were excluded from analyses of Day 365. Predictors of the fold-rise between Day 0 and Day 21 and predictors of the rate of change between Day 21 and Day 365 were examined using linear regression models. Induction of memory B-cell responses was summarized as geometric mean percentages (GMP) ratio following estimation of means and differences in means of GMPs at days 0 and 21, as previously described¹⁶. All analyses were conducted using SAS statistical software (version 9.3; SAS Institute, Inc., Cary, NC).

Results

A total of 92 participants with type 2 diabetes (70 in Wisconsin and 22 in Pennsylvania [Supplemental Table 1]) and 113 non-diabetic individuals (80 in Wisconsin and 33 in Pennsylvania) were enrolled before the 2011–2012 influenza season; proportions of enrollees with diabetes were similar at both enrollment sites (Supplemental Table 1). Diabetic enrollees were more likely to be male ($p=0.03$) and were older ($p=0.001$) than non-diabetic enrollees. Diabetics enrollees also had higher BMI ($p<0.001$), were more likely to be obese (BMI ≥ 30 , $p<0.001$), and had lower self-rated general health status ($p<0.001$). Among 88 diabetics for whom hemoglobin A1c was available, 48 (55%) had controlled diabetes (HbA1c $\leq 7.0\%$) (data not shown)¹⁷. There were no differences between diabetic and non-diabetic adults in self-rated functional status measures (Supplemental Table 2). A total of 190 (93%)

participants (84 [91%] diabetic patients and 106 [94%] non-diabetic patients) returned before the 2012–2013 influenza season and provided a day 365 (D365) serum specimen.

Pre-vaccination (D0), post-vaccination (D21) and D365 HI titers were measured for three 2011–2012 serology reference viruses (A/California/07/2009 [H1N1pdm09], A/Victoria/210/2009 [H3N2], and B/Brisbane/60/2008 [Victoria]) and two 2012–2013 reference viruses (A/Victoria/361/2011 [H3N2] and B/Wisconsin/01/2010 [Yamagata]) (Figure). Baseline titer and percent seroprotection at D0 and D365 did not differ by diabetes status (Table). Percent seroprotection at day 21 (D21) was significantly higher for non-diabetics for influenza A(H3N2) viruses but was similar for influenza A(H1N1)pdm09 and influenza B viruses. Pre- and post-vaccination GMT ratios (i.e., D21/D0) did not differ significantly by diabetes status. From the linear regression model, only pre-vaccination titer was significantly associated (negatively) with D21/D0 GMT ratio when controlling for age and diabetes status; participants with higher pre-vaccination titers had lower D21/D0 GMT ratios for all antigens tested (data not shown). Consistent with GMT ratios, induction of vaccine-specific memory B cells (IgG, IgM and IgA) at D21 was comparable between diabetic and non-diabetic persons (Supplemental Table 4).

HI titers were measured for four reference viruses for participants who returned for the D365 specimen collection (Figure). D365/D21 GMT ratios did not differ by diabetes status for any of the antigens measured ($p>0.05$); 56-64% of diabetic and 58-68% of non-diabetic adults had seroprotective HI titers ≥ 40 against vaccine viruses one year after vaccination (Table, D365 values). Furthermore, diabetes was not a significant predictor in the linear regression model where the rate of decline in antibody titer was the outcome for the antigens measured (Supplemental Table 3). Extrapolating from antibody declines from D21 to D365, assuming linear trends, the estimated number of days until post-vaccination HI titers decreased 2-fold would be 675 days for A/California/07/2009, 717 days for B/Brisbane/60/2008, 1075 for B/Wisconsin/01/2010 and 294 for the 2012-2013 H3N2 virus A/Victoria/361/2011. From the linear regression model controlling for age and diabetes status, antibody titer at D21 was the only significant predictor of the rate of antibody decline (Supplemental Table 3). Participants with higher D21 post-vaccination titers had steeper decline over the 12-month period. Diabetes, age, vitamin D level, and BMI were not significant predictors for any of the viruses tested.

133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158

Discussion

In this study, adults aged 50-80 years with and without type 2 diabetes mellitus exhibited similar serologic response to influenza vaccination and persistence of elevated antibody titers. Both diabetic and non-diabetic adults responded to inactivated influenza vaccine. Seroconversion was similar against all vaccine components, as well as seroprotection against A(H1N1)pdm09 and B virus vaccine components, while seroprotection against the influenza A(H3N2) virus vaccine component was higher among adults without diabetes compared to non-diabetic adults. Diabetes was not significantly associated with antibody response or induction of memory B cells to vaccine components in models controlling for age, obesity and other potential predictors of response. Pre-vaccination HI titer was the strongest predictor of post-vaccination (D21) titer, with lower pre-vaccination HI titers associated with greater fold-rise in D21/D0 GMT ratio. These results are consistent with previous serologic studies that showed no impairment of initial immune responses to vaccine among adults with diabetes^{3,4}. Declines in antibody titers were also similar among diabetic and non-diabetic adults; excluding subjects with serologic evidence of infection during the 2011-2012 season (Table, D365 values).

Among patients enrolled in this study, we observed no differences in the relationship between diabetes status and HI titer by subject age. One study found improved immune response to influenza vaccination among diabetics compared to non-diabetic older adults (aged ≥ 65 years), while no difference was observed among immune response in younger adults¹⁸.

The current study provides more detail about the magnitude and duration of antibody responses to influenza vaccine in a well-characterized group of older adults than previous studies by assessing changes in GMTs rather than only seroconversion and seroprotection. One important finding of this study was the rates of waning of antibody titers among diabetic adults, which were similar to those reported among healthy adults who received inactivated influenza vaccine in a clinical trial which found that HI titers decreased slowly over 18 months¹¹.

These results are subject to several limitations. This study only included individuals with type 2 diabetes and may not be applicable to influenza vaccine response and duration of response in individuals with type 1 diabetes ⁷. Enrollees may differ from non-participants in their level of control of diabetes, prevalence of comorbidities, or behaviors (such as smoking) associated with immune response. Furthermore, no surveillance was conducted among enrolled individuals to identify influenza infections during 2011-12 season which may have contributed to a rise in HI titer; not all patients with increased HI titers excluded from analysis of duration of antibody response may have had influenza infection. Additionally, we were unable to evaluate whether or not medications influenced serologic response. Finally, HI titers are imprecise correlates of protection; we use HI titers ≥ 40 as a widely accepted correlate of 50% protection against influenza illness among adults ¹⁹.

In conclusion, diabetic and non-diabetic adults appear to respond similarly to influenza vaccination and retain elevated antibody levels until a subsequent season. Efforts should continue to increase influenza vaccination coverage among all adults, especially those at increased risk of severe disease, such as people with diabetes.

174 REFERENCES

- 175 1. Athamneh LN, Sansgiry SS. Influenza vaccination in patients with diabetes: disparities in prevalence between
176 African Americans and Whites. *Pharmacy practice* 2014;12(2):410. [published Online First: 2014/07/19]
- 177 2. Burney LE. Influenza immunization: Statement. *Public Health Rep* 1960;75(10):944.
- 178 3. McElhaney JE, Garneau H, Camous X, et al. Predictors of the antibody response to influenza vaccination in
179 older adults with type 2 diabetes. *BMJ Open Diabetes Res Care* 2015;3(1):e000140. doi: 10.1136/bmjdr-
180 2015-000140
- 181 4. Sheridan PA, Paich HA, Handy J, et al. The antibody response to influenza vaccination is not impaired in type 2
182 diabetics. *Vaccine* 2015;33(29):3306-13. doi: 10.1016/j.vaccine.2015.05.043
- 183 5. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative
184 review. *Vaccine* 2006;24(8):1159-69. doi: 10.1016/j.vaccine.2005.08.105
- 185 6. Lin CJ, Martin JM, Cole KS, et al. Are children's vitamin D levels and BMI associated with antibody titers
186 produced in response to 2014-2015 influenza vaccine? *Hum Vaccin Immunother* 2017;1-5. doi:
187 10.1080/21645515.2017.1299837
- 188 7. Nam J, Kim A, Yoon J, et al. The humoral immuneresponse to the inactivated influenza A (H1N1) 2009
189 monovalent vaccine in patients with Type 2 diabetes mellitus in Korea. *Diabet Med* 2011;28:815-7.
- 190 8. Sheridan PA, Paich HA, Handy J, et al. Obesity is associated with impaired immune response to influenza
191 vaccination in humans. *Int J Obes (Lond)* 2012;36(8):1072-7. doi: 10.1038/ijo.2011.208
- 192 9. Black S, Nicolay U, Del Giudice G, et al. Influence of Statins on Influenza Vaccine Response in Elderly
193 Individuals. *J Infect Dis* 2016;213(8):1224-8. doi: 10.1093/infdis/jiv456
- 194 10. Ganatra RB, McKenna JJ, Bramley AM, et al. Adults with diabetes hospitalized with pandemic influenza
195 A(H1N1)pdm09--U.S. 2009. *Diabetes Care* 2013;36(7):e94. doi: 10.2337/dc13-0005
- 196 11. Petrie JG, Ohmit SE, Johnson E, et al. Persistence of Antibodies to Influenza Hemagglutinin and
197 Neuraminidase Following One or Two Years of Influenza Vaccination. *J Infect Dis* 2015;212(12):1914-22.
198 doi: 10.1093/infdis/jiv313
- 199 12. Petrie JG, Ohmit SE, Truscon R, et al. Modest Waning of Influenza Vaccine Efficacy and Antibody Titers
200 During the 2007-2008 Influenza Season. *J Infect Dis* 2016;214(8):1142-9. doi: 10.1093/infdis/jiw105
- 201 13. Ross TM, Lin CJ, Nowalk MP, et al. Influence of pre-existing hemagglutination inhibition titers against
202 historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50-80
203 years of age. *Hum Vaccin Immunother* 2014;10(5):1195-203. doi: 10.4161/hv.28313
- 204 14. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and Control of Seasonal Influenza with Vaccines.
205 *MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and*
206 *reports* 2016;65(5):1-54. doi: 10.15585/mmwr.rr6505a1 [published Online First: 2016/08/26]
- 207 15. WHO Global Influenza Surveillance Network. Serological diagnosis of influenza by haemagglutination
208 inhibition testing. Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva,
209 Switzerland: World Health Organization, 2011.
- 210 16. Reber AJ, Kim JH, Biber R, et al. Preexisting Immunity, More Than Aging, Influences Influenza Vaccine
211 Responses. *Open Forum Infect Dis* 2015;2(2):ofv052. doi: 10.1093/ofid/ofv052
- 212 17. Pinchevsky Y, Butkow N, Chirwa T, et al. Glycaemic, blood pressure and cholesterol control in 25 629
213 diabetics. *Cardiovascular journal of Africa* 2015;26(4):188-92. doi: 10.5830/cvja-2015-050 [published
214 Online First: 2015/09/26]
- 215 18. Frasca D, Diaz A, Romero M, et al. Young and elderly patients with type 2 diabetes have optimal B cell
216 responses to the seasonal influenza vaccine. *Vaccine* 2013;31(35):3603-10. doi:
217 10.1016/j.vaccine.2013.05.003
- 218 19. Dunning AJ, DiazGranados CA, Voloshen T, et al. Correlates of Protection against Influenza in the Elderly:
219 Results from an Influenza Vaccine Efficacy Trial. *Clin Vaccine Immunol* 2016;23(3):228-35. doi:
220 10.1128/CVI.00604-15

223 **Footnotes:**

224 Conflicts of interest: KKM, MPN and RZ have received research funds from Merck & Co., Inc and Pfizer, Inc.

225 KKM and RZ have received research funds from Sanofi Pasteur, Inc. LC is currently employed by Novartis. The

226 remaining authors report no conflicts of interest.

227 Funding: This study was supported by cooperative agreements U01 IP000471 and U01 IP000467 from the

228 Centers for Disease Control and Prevention. The findings and conclusions in this report are those of those authors

229 and do not necessarily represent the views of the Centers for Disease Control and Prevention.

230 Corresponding author: Jessie Chung, jchung@cdc.gov

231

Table. Pre- and post-vaccination hemagglutination inhibition (HI) titers to influenza vaccine reference antigens among individuals aged 50-80 years with and without type 2 diabetes mellitus.

	Diabetic Patients			Non-Diabetic Patients			p-value ¹
		GMT or GMT ratio	% sero-		GMT or GMT ratio	% sero-	
	no.	(95% CIs)	protection	no.	(95% CIs)	protection	
A/California/07/2009 (H1N1)							
D0	92	16.2 (12.5, 21.0)	30	113	19.4 (15.3, 24.6)	34	0.5
D21	92	45.9 (35.3, 59.8)	65	113	54.1 (43.3, 67.6)	67	0.7
D365 ^{2,3}	82	31.0 (23.9, 40.2)	56*	102	42.1 (33.0, 53.7)	58*	0.8
D21 / D0	92	2.8 (2.2, 3.7)		113	2.8 (2.3, 3.4)		
D365 / D21 ^{2,3}	82	0.6 (0.5, 0.8)		102	0.8 (0.6, 0.9)		
A/Victoria/210/2009 (H3N2)							
D0	92	21.2 (16.2, 27.7)	47	113	24.0 (18.7, 30.9)	50	0.4
D21	92	67.3 (51.1, 88.8)	79	113	97.4 (77.3, 122.8)	91	0.01
D21 / D0	92	3.2 (2.5, 4.1)		113	4.1 (3.1, 5.3)		
A/Victoria/361/2011 (H3N2)							
D0	92	28.8 (22.1, 37.5)	38	113	31.8 (24.9, 40.7)	45	0.7
D21	92	79.7 (61.3, 103.6)	73	113	114.0 (91.4, 142.4)	87	0.02
D365 ^{2,4}	83	35.3 (27.8, 44.6)	58*	104	53.8 (42.9, 67.3)	67*	0.2
D21 / D0	92	2.8 (2.2, 3.5)		113	3.6 (2.7, 4.7)		
D365 / D21 ^{2,4}	83	0.4 (0.4, 0.5)		104	0.5 (0.4, 0.5)		
B/Brisbane/60/2008 (B Victoria)							
D0	92	34.7 (27.7, 43.4)	56	113	25.4 (20.9, 31.0)	48	0.2
D21	92	57.3 (46.9, 70.1)	75	113	52.3 (43.2, 63.3)	71	0.6
D365 ^{2,5}	81	41.3 (33.8, 50.5)	64*	103	38.7 (32.4, 46.2)	59*	0.5
D21 / D0	92	1.7 (1.4, 2.0)		113	2.1 (1.7, 2.5)		
D365 / D21 ^{2,5}	81	0.7 (0.6, 0.8)		103	0.7 (0.6, 0.9)		
B/Wisconsin/01/2010 (B Yamagata)							
D0	92	22.7 (18.2, 28.2)	37	113	26.2 (21.3, 32.2)	47	0.2
D21	92	37.0 (29.5, 46.3)	58	113	46.3 (37.1, 57.7)	61	0.6
D365 ^{2,6}	60	34.1 (25.9, 45.1)	60*	84	43.7 (34.6, 55.1)	68*	0.6

D21 / D0	92	1.6 (1.3, 2.0)	113	1.8 (1.4, 2.2)
D365 / D21 ^{2,6}	60	0.9 (0.7, 1.1)	84	0.8 (0.7, 1.0)

GMT=geometric mean titer, D0=day 0, D21=day 21, D365=day 365.

¹ P-value for comparison of percent sero-protection (hemagglutination inhibition [HI] titer $\geq 1:40$) among patients with and without diabetes.

² Limited to subjects who completed 12-month follow-up.

³ Excludes 6 subjects due to serologic evidence of natural infection (4-fold rise with GMT ≥ 40 at D365 between D21 and D365 to A/California/07/2009).

⁴ Excludes 3 subjects due to serologic evidence of natural infection with A/Victoria/11(H3N2)-like virus.

⁵ Excludes 6 subjects due to serologic evidence of natural infection with B/Brisbane/60/2008-like virus.

⁶ Excludes 46 subjects due to serologic evidence of natural infection B/Wisconsin/1/2012-like virus.

*56-64% of diabetic and 58-68 % of non-diabetic adults had seroprotective HI titers ≥ 40 against vaccine viruses one year after vaccination.

Figure. Pre- and post-vaccination¹ hemagglutination inhibition (HI) titers to influenza vaccine reference antigens among individuals aged 50-80 years with and without type 2 diabetes mellitus²

¹D0 pre-vaccination, D21 post-vaccination, and D326 post-vaccination

²Figure represents linear approximations

A/California/07/2009 (H1N1pdm09)

B/Brisbane/60/2008 (B/Victoria)

B/Wisconsin/1/2012 (B/Yamagata)

A/Victoria/361/2011 (H3N2)